MRK stock - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

VA Tech Wabag (NSE: WABAG) wins order from CMWSSB for 45 MLD Chennai TTRO plant

Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway

Representative image of enterprise cloud cybersecurity infrastructure illustrating how Accenture plc and Google Cloud are strengthening cloud security defenses against AI-driven cyber threats and multi-cloud security risks.

How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure

Four-decade-first: Lok Sabha votes down no-confidence motion against Speaker Om Birla

Merck’s KEYTRUDA (pembrolizumab) demonstrated a survival benefit in platinum-resistant ovarian cancer during the KEYNOTE-B96 trial, drawing renewed investor attention to MRK stock performance.

Read More

6 minute read

Pharma Industry News

Merck’s KEYNOTE-B96 trial signals survival benefit in platinum-resistant ovarian cancer, but MRK stock dips

Merck's KEYNOTE-B96 trial shows survival benefit in ovarian cancer. See what it means for patients, pipeline, and MRK stock. Read full analysis now.

October 17, 2025

web analytics